Fingolimod Hydrochloride and FluMist 2018-2019 nasal
Determining the interaction of Fingolimod Hydrochloride and FluMist 2018-2019 nasal and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:If you are currently being treated or have recently been treated with fingolimod, you should talk to your doctor before receiving influenza virus vaccine, live. Depending on the dose and length of time you have been on fingolimod, you may be at risk for developing an infection from the vaccine or have a reduced response to the vaccine. In some situations, your doctor may want to delay vaccination to give your body time to recover from the effects of fingolimod therapy. If you have recently been vaccinated with influenza virus vaccine, live, your doctor may choose to postpone treatment with fingolimod for a month. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: The administration of live, attenuated viral or bacterial vaccines during fingolimod therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Fingolimod causes reversible sequestration of lymphocytes in lymphoid tissues. A dose-dependent reduction in peripheral lymphocyte count to 20% to 30% of baseline values has been observed, which may increase the risk of infections. Vaccination may also be less effective during and for up to two months after discontinuation of fingolimod therapy. In healthy volunteers administered keyhole limpet Hemocyanin (KLH) and pneumococcal polysaccharide vaccine (PPV-23), antigen-specific IgM titers were decreased by 91% and 25% in response to KLH and PPV, respectively, in subjects receiving fingolimod 0.5 mg compared to placebo. Similarly, IgG titers were decreased by 45% and 50% in response to KLH and PPV, respectively, in subjects receiving fingolimod 0.5 mg compared to placebo. The responder rate for fingolimod 0.5 mg as measured by the number of subjects with a >4-fold increase in KLH IgG was comparable to placebo and 25% lower for PPV-23 IgG, while the number of subjects with a >4 fold increase in KLH and PPV-23 IgM was 75% and 40% lower, respectively, compared to placebo.
MANAGEMENT: The use of live attenuated vaccines should be avoided during and for two months after treatment with fingolimod. In patients who have recently been vaccinated, fingolimod therapy should be postponed for one month to allow the full effect of vaccination to occur.
- "Product Information. Meruvax II (rubella virus vaccine, live)." Merck & Co, Inc, West Point, PA.
- "Product Information. Gilenya (fingolimod)." Novartis Pharmaceuticals, East Hanover, NJ.
- CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18
- Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison's Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):
- "Product Information. Attenuvax (measles virus vaccine, live, attenuated)." Merck & Co, Inc, West Point, PA.
Generic Name: fingolimod
Brand name: Gilenya
Synonyms: Fingolimod
Generic Name: influenza virus vaccine, live, trivalent
Brand name: FluMist 2018-2019, FluMist Quadrivalent, Flumist, FluMist 2010-2011, FluMist 2011-2012, FluMist 2012-2013, FluMist 2013-2014, FluMist 2014-2015, FluMist 2015-2016, FluMist 2016-2017, FluMist Quadrivalent 2019-2020
Synonyms: FluMist Nasal Spray, Flumist
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Fingolimod Hydrochloride-FluMist Quadrivalent
- Fingolimod Hydrochloride-FluMist Quadrivalent 2015-2016 Formula
- Fingolimod Hydrochloride-Flunisolide
- Fingolimod Hydrochloride-Flunisolide (Oral Inhalation)
- Fingolimod Hydrochloride-Flunisolide eent
- Fingolimod Hydrochloride-Flunisolide inhalation
- FluMist 2018-2019 nasal-Fioricet
- FluMist 2018-2019 nasal-Fioricet Capsules
- FluMist 2018-2019 nasal-Fioricet Oral
- FluMist 2018-2019 nasal-Fioricet with Codeine
- FluMist 2018-2019 nasal-Fiorinal
- FluMist 2018-2019 nasal-Fiorinal w/Codeine